SMITH & NEPHEW PLC
3 May 2023
NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ("PDMR") AND PERSONS CLOSELY ASSOCIATED WITH THEM.
| Reason for the notification | |
| Initial notification /Amendment | Initial notification |
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| Name | Smith & Nephew plc |
| LEI | 213800ZTMDN8S67S1H61 |
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| Description of the financial instrument, type of instrument | Smith & Nephew plc ordinary shares of USD 0.20 each |
| Identification code | ISIN: GB0009223206 |
| Nature of the transaction | Sale of ordinary shares. Following the sale, each individual continues to maintain a shareholding in accordance with the shareholding guidelines. |
| Date of Transaction | Phil Cowdy: 2023 - 04 - 27 & Bradley Cannon: 2023 - 05 - 02 |
| Place of Transaction | London Stock Exchange (XLON) |
| Name (Position) | Director / PDMR | Price (£) | Volume | Aggregated information | Total Ordinary Share Holding following the transaction * | Total Ordinary Share Holding as a % of the Company's ISC following the transaction * |
| Phil Cowdy (Chief Corporate Development and Corporate Affairs Officer) | PDMR | 12.83280 | 12,083 | N/A Single Transaction | 49,000.99309 ordinary shares | 0.00558% |
| Bradley Cannon (President, Global Orthopaedics) | PDMR | 12.926813 | 9,500 | N/A Single Transaction | 117,819.37494 ordinary shares (including 3,599.09977 in ADS') | 0.01342% |
* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.
Helen Barraclough
Company Secretary
Smith & Nephew plc
Tel: +44 (0)1923 477100
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
